GILD.TO Gilead Sciences CDR (CAD Hedged)

Healthcare Drug Manufacturers - General Toronto Exchange
- CAD
Market cap
-
P/E
-
P/B
15.29x
ROE
-61.8%
Dividend yield
1.62%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GILD.TO undervalued?

Graham number

The Graham number of Gilead Sciences CDR (CAD Hedged) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Gilead Sciences CDR (CAD Hedged) fundamental analysis

No fundamental analysis for Gilead Sciences CDR (CAD Hedged) yet.

Gilead Sciences CDR (CAD Hedged) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Gilead Sciences CDR (CAD Hedged)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatmen…

Full company profile